These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 35132676)

  • 1. The impact of National Centralised Drug Procurement policy on the use of policy-related original and generic drugs in China.
    Yang Y; Hu R; Geng X; Mao L; Wen X; Wang Z; Hao S; Cui D; Mao Z
    Int J Health Plann Manage; 2022 May; 37(3):1650-1662. PubMed ID: 35132676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
    Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
    BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis.
    Wang X; He X; Zhang P; Zhang M; Ma R; Dai R; Li X
    Int J Equity Health; 2023 Sep; 22(1):200. PubMed ID: 37770924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of '4+7' volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China.
    Wang J; Yang Y; Xu L; Shen Y; Wen X; Mao L; Wang Q; Cui D; Mao Z
    BMJ Open; 2022 Mar; 12(3):e054346. PubMed ID: 35288385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.
    Zhao B; Wu J
    Int J Health Policy Manag; 2023; 12():7724. PubMed ID: 38618801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018-2019: an interrupted time-series analysis.
    Yang Y; Chen L; Ke X; Mao Z; Zheng B
    BMC Health Serv Res; 2021 Jul; 21(1):668. PubMed ID: 34238290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis.
    Wang N; Yang Y; Xu L; Mao Z; Cui D
    BMC Public Health; 2021 Oct; 21(1):1883. PubMed ID: 34663282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A quasi-experimental study of the volume-based procurement (VBP) effect on antiviral medications of hepatitis B virus in China.
    Wen X; Xu L; Chen X; Wu R; Luo J; Wan Y; Mao Z
    Front Pharmacol; 2023; 14():984794. PubMed ID: 37731741
    [No Abstract]   [Full Text] [Related]  

  • 9. The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis.
    Wen X; Yin S; Cui L; Mao L; Lin Z; Yaermaimaiti Z; Geng X; Li Y; Yang Y; Cui D; Mao Z
    Front Public Health; 2021; 9():718013. PubMed ID: 34760861
    [No Abstract]   [Full Text] [Related]  

  • 10. The change of drug utilization in China's public healthcare institutions under the "4 + 7" centralized drug procurement policy: Evidence from a natural experiment in China.
    Lu J; Long H; Shen Y; Wang J; Geng X; Yang Y; Mao Z; Li J
    Front Pharmacol; 2022; 13():923209. PubMed ID: 36081942
    [No Abstract]   [Full Text] [Related]  

  • 11. The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China.
    Chen L; Yang Y; Luo M; Hu B; Yin S; Mao Z
    Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33334027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series.
    Long H; Yang Y; Geng X; Mao Z; Mao Z
    Front Pharmacol; 2022; 13():944540. PubMed ID: 35910351
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of the National Centralized Drug Procurement Policy (4 + 7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series.
    Lan T; Guan L; Pang X; Li X; Yu Q
    J Clin Pharm Ther; 2022 Jan; 47(1):104-111. PubMed ID: 34668203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impacts of the national centralized drug procurement policy on the use of policy-related antibiotic agents: the case of Shaanxi province, China.
    Yang C; Ye D; Yan K; Xiang C; Liu S; Gu J; Liu Y; Fang Y
    Expert Rev Anti Infect Ther; 2023 Jun; 21(6):675-684. PubMed ID: 37013799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impacts of national volume-based drug procurement policy on the utilization and costs of antihypertensive drugs in a Chinese medicine hospital: an interrupted time series analysis of 5138 patients.
    Shang L; Cheng Y; Zhou J; Bao Y; Kong D; Huang R; Chen Y; Wang H; Gu N; Ma A
    Front Pharmacol; 2024; 15():1302154. PubMed ID: 38389928
    [No Abstract]   [Full Text] [Related]  

  • 16. The impacts of national centralized drug procurement policy on drug utilization of medical institutions: an empirical study in a county-level hospital in China.
    Li H; Lin F; Wang R; Zhu C; Cao K; Chen Y; Fang G; Li J; Ding J; Li W
    BMC Health Serv Res; 2024 Apr; 24(1):513. PubMed ID: 38658940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls.
    Chen Y; Ji X; Xiao H; Unger JM; Cai Y; Mao Z; Yeung K
    Front Pharmacol; 2021; 12():804237. PubMed ID: 35815118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impacts of the "4+7" pilot policy on the volume, expenditures, and daily cost of Serotonin-Specific Reuptake Inhibitors (SSRIs) antidepressants: A quasi-experimental study.
    Wen X; Wang Z; Xu L; Luo J; Geng X; Chen X; Yang Y; Cui D; Mao Z
    Front Pharmacol; 2022; 13():829660. PubMed ID: 36060003
    [No Abstract]   [Full Text] [Related]  

  • 19. The vacated space of volume/price of the drugs centralized procurement with quantity in secondary and above public hospitals of China.
    Wang J; Zhang S; Wang C; Li J; Wang R; Zhu L
    BMC Health Serv Res; 2024 Jun; 24(1):771. PubMed ID: 38951849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of National Centralized Drug Procurement policy on chemical pharmaceutical enterprises' R&D investment: a difference-in-differences analysis in China.
    Li J; Zhang X; Wang R; Cao K; Wan L; Ren X; Ding J; Li W
    Front Public Health; 2024; 12():1402581. PubMed ID: 39011324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.